Cambridge Innovation Capital
Michael is an Investment Director at Cambridge Innovation Capital (CIC), specializing in healthcare investments. He brings expertise to the sector through his experience in research, strategy consulting, startups, and venture capital investing.
Before joining CIC, Michael was a Principal in the Healthcare Practice Area at the Toronto office of the Boston Consulting Group (BCG). In this role, he advised multinational healthcare companies across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A.
Michael is also a co-founder of Proteorex Therapeutics, a Canadian biotechnology company developing small molecule therapeutics for “hard to drug” targets implicated in disease.
Prior to BCG, Michael worked at Oxford Capital Partners where he focused on investing in early-stage healthcare and life science businesses. Before Oxford Capital, Mike was an academic researcher in the field of neurobiology and authored papers published in a number of leading academic journals, including Science.
Education, Personal, and Fellowship
Mike graduated with a 1st Class Honors degree in biology from Queen’s University, Canada, and earned his DPhil in zoology from Oxford University, where he was the Hope Scholar.
Michael served his fellowship at Cambridge Innovation Capital under the mentorship of CIC’s CEO, Victor Christou. He is a member of Class 22.